文献速递睡眠呼吸障碍

TOS/OMA/OAC联合专家指导声明:基于GRADE方法对超重或肥胖美国成人药物治疗的管理

Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach
RSS 订阅 · 指南共识 · 呼吸支持与睡眠 · 2026-03-05

肥胖影响超过40%美国成人,却仍诊断和治疗不足。TOS、OMA与OAC组建多学科专家组,采用GRADE方法系统评价证据,对多种FDA批准减肥药物及特定肥胖并发症给出推荐,并为体重维持期继续用药给出强推荐。

要点

  • 对安非他酮-纳曲酮、司美格鲁肽、替尔泊肽和司美拉诺肽作出强推荐,证据确定性为中等。
  • 对其他药物及阻塞性睡眠呼吸暂停、射血分数保留的心力衰竭等特定并发症给出条件推荐。
  • 体重维持期间继续使用减肥药物获得强推荐。

核心结论

  • 肥胖是一种慢性、常呈进展性的疾病,需要全面、长期且以人为中心的照护。
  • 有效的减肥药物已经存在,但因系统性障碍而未被充分利用。
  • 扩大可及性、减少污名化并确保公平覆盖,对于将科学进步转化为人群健康收益至关重要。
  • 未来优先事项包括在基层医疗中实现全面肥胖照护的可及与整合、改善可负担性、填补研究空白、开展头对头试验,并随着证据演进更新指导。

研究设计与样本

  • 肥胖学会(TOS)、肥胖医学协会(OMA)与肥胖行动联盟(OAC)组建了包括患者代表和肥胖照护提供者在内的多学科专家组。
  • 采用推荐分级的评估、制定与评价(GRADE)方法制定指导声明。
  • 通过Epistemonikos数据库进行系统证据合成,优先考虑体重下降、生活质量、不良事件和肥胖并发症改善等临床相关结局。
  • 通过共识研讨会制定推荐,并基于证据确定性、获益、危害、公平性和可行性,使用GRADE证据到决策框架将推荐分级为强推荐或条件推荐。

主要发现

  • 专家组就FDA批准的减肥药物给出推荐,包括奥利司他、安非他酮-纳曲酮、芬特明、芬特明-托吡酯、利拉鲁肽、司美格鲁肽、替尔泊肽和司美拉诺肽。
  • 对安非他酮-纳曲酮、司美格鲁肽、替尔泊肽和司美拉诺肽作出强推荐,证据确定性为中等。
  • 对其他药物及特定肥胖并发症(阻塞性睡眠呼吸暂停、射血分数保留的心力衰竭、代谢功能障碍相关脂肪性肝病/代谢功能障碍相关脂肪性肝炎、骨关节炎、主要不良心血管事件和2型糖尿病)作出条件推荐。
  • 体重维持期间继续使用减肥药物获得强推荐。

关键数值与推荐

  • 对安非他酮-纳曲酮、司美格鲁肽、替尔泊肽和司美拉诺肽的强推荐基于中等确定性证据。
  • 对其他药物及特定肥胖并发症给出条件推荐。
  • 体重维持期间继续使用减肥药物为强推荐。

临床怎么用

  • 肥胖影响超过40%美国成人,重度肥胖呈上升趋势。
  • 尽管肥胖被认定为慢性病,但仍诊断不足和治疗不足,获得循证肥胖治疗的机会有限。
  • 肥胖治疗的障碍包括社会经济差异、临床医生培训有限、污名化以及限制性或缺失的报销政策。
  • 专家组强调扩大可及性、减少污名化并确保公平覆盖,以将科学进步转化为人群健康收益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「局限性」,故未列出该栏;全文请点「阅读原文」。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Obesity (Silver Spring). 2026 Apr;34(4):851-870. doi: 10.1002/oby.70164. Epub 2026 Mar 5. ABSTRACT BACKGROUND: Obesity affects over 40% of US adults, with severe obesity on the rise. Despite recognition of obesity as a chronic disease, it remains underdiagnosed and undertreated. Access to evidence-based obesity treatment is limited, leading to increased obesity severity and related complications. Barriers to obesity treatment include socioeconomic disparities, limited clinician training, stigma, and restrictive or absent reimbursement policies. FDA-approved obesity medications offer significant health benefits, prompting the need for updated, evidence-based guidance. METHODS: The Obesity Society (TOS), the Obesity Medicine Association (OMA), and the Obesity Action Coalition (OAC) convened a multidisciplinary panel, including patient representatives and obesity care providers, to develop a guidance statement using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Systematic evidence synthesis was conducted via Epistemonikos databases, with outcomes prioritized for clinical relevance, including weight reduction, quality of life, adverse events, and improvements in obesity complications. Recommendations were developed through consensus workshops and graded as strong or conditional based on evidence certainty, benefits, harms, equity, and feasibility using the GRADE Evidence-to-Decision framework. RESULTS: The panel issued recommendations on FDA-approved obesity medications including orlistat, bupropion-naltrexone, phentermine, phentermine-topiramate, liraglutide, semaglutide, tirzepatide, and setmelanotide. Strong recommendations were made for bupropion-naltrexone, semaglutide, tirzepatide, and setmelanotide, with moderate-certainty evidence. Conditional recommendations were made for other agents and specific obesity complications (obstructive sleep apnea, heart failure with preserved ejection fraction, metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis, osteoarthritis, major adverse cardiovascular events, and type 2 diabetes). Continuing obesity medications during weight maintenance received a strong recommendation. CONCLUSION: Obesity is a chronic, often progressive, disease requiring comprehensive, long-term, and person-centered care. Effective obesity medications exist but remain underutilized due to systemic barriers. Expanding access, reducing stigma, and ensuring equitable coverage are essential to translating scientific advances into population health gains. Future priorities include access and integration of comprehensive obesity care in the primary care setting, improving affordability, addressing research gaps, conducting head-to-head trials, and updating guidance as evidence evolves.

来源:指南共识 · 呼吸支持与睡眠,查看原文。版权归原作者所有。

引用

  1. 指南共识 · 呼吸支持与睡眠:Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。